Copyright: ©Author(s) 2026.
World J Nephrol. Sep 25, 2026; 15(3): 120318
Published online Sep 25, 2026. doi: 10.5527/wjn.v15.i3.120318
Published online Sep 25, 2026. doi: 10.5527/wjn.v15.i3.120318
Table 1 Baseline characteristics of the studied groups, n (%)/mean ± SD
| Variables | Inactive LN group (n = 50) | Active LN group (n = 50) | P value |
| Age (years) | 28.88 ± 5.83 | 30.56 ± 8.08 | 0.23 |
| Sex | 0.18 | ||
| Male | 17 (34) | 12 (24) | |
| Female | 33 (66) | 38 (76) | |
| Body mass index (kg/m2) | 24.57 ± 6.78 | 23.09 ± 4.48 | 0.78 |
| Duration of disease (years) | 7.68 ± 2.98 | 9.87 ± 3.45 | 0.02 |
| Number of relapses | 3 (6) | 5 (10) | 0.48 |
- Citation: Azoz NM, Ammar AA, Nafady HA, Gadelkareem RA, Abdel Aziz EM, Elzohne RA. Role of fibroblast growth factor-23 in renal disease activity and bone density involvement in patients with lupus nephritis. World J Nephrol 2026; 15(3): 120318
- URL: https://www.wjgnet.com/2220-6124/full/v15/i3/120318.htm
- DOI: https://dx.doi.org/10.5527/wjn.v15.i3.120318